Used in targeted protein degradation therapies, particularly in oncology and immunomodulatory treatments. It functions by binding to the cereblon (CRBN) E3 ubiquitin ligase complex, redirecting its activity to mark specific disease-related proteins for proteasomal degradation. This mechanism is leveraged in the development of drugs for hematologic cancers such as multiple myeloma and myelodysplastic syndromes. Additionally, CRBN modulator-1 serves as a key scaffold in designing molecular glues and PROTACs (proteolysis-targeting chimeras), enabling selective degradation of previously undruggable targets. Its application extends to research tools for studying protein homeostasis and ubiquitin-proteasome system dynamics.